Tan­go Ther­a­peu­tics nabs $60M in CRISPR-based hunt for hid­den can­cer genes

6 years ago
Financing
R&D

Hunt­ing a full OK for Baven­cio in front­line blad­der can­cer, Pfiz­er, Mer­ck KGaA re­ceive VIP treat­ment at FDA

6 years ago
Pharma
FDA+

Fred­er­ic Pla en­list­ed as COO at the Park­er In­sti­tute; For­mer Alk­er­mes ex­ec named CMO at Seres Ther­a­peu­tics

6 years ago
Peer Review

Covid-19 roundup: Pfiz­er hus­tling up mil­lions of dos­es of vac­cine — de­tails $748M BioN­Tech deal; CDC tweaks stance ...

6 years ago
Coronavirus

Qim­ing's Chi­na-fo­cused $1.1B new fund brings glob­al haul to $5B with­in 1 week — but the dis­tri­b­u­tion won't be even

6 years ago
Financing
China

Did Gilead just low­er the bar on cru­cial remde­sivir tri­als for Covid-19? Switch­ing end­points, amp­ing up tri­al size ...

6 years ago
R&D
Coronavirus

Keytru­da nabs an­oth­er pri­or­i­ty re­view; Quell ties up CAR pact with Han­nover Med­ical School

6 years ago
News Briefing

Com­pound­ing drugs dur­ing the pan­dem­ic: FDA of­fers pol­i­cy clar­i­fi­ca­tions

6 years ago
FDA+

Weath­er­ing the storm: An­oth­er biotech braves Covid-19 in up­sized IPO

6 years ago
Financing
Startups

FDA needs three more months to re­view Roche's SMA drug — giv­ing Bio­gen, No­var­tis some re­lief

6 years ago
FDA+

Zai Lab finds lat­est tar­get in Re­gen­eron’s bis­pe­cif­ic, pay­ing up to $190M for Chi­nese rights

6 years ago
Deals
R&D

Covid-19 roundup: EU‘s top sci­en­tist re­signs in re­buke to agency’s Covid re­sponse; J&J posts neg­a­tive da­ta for ...

6 years ago
Coronavirus

Ac­celeron's PAH drug gets the FDA's red car­pet treat­ment with break­through sta­tus

6 years ago
R&D
FDA+

Roche makes a plat­form play, bet­ting $190M in cash on Ar­rakis’ long-haul plans to drug RNA

6 years ago
Deals

‘If grippe con­demns, the sec­ondary in­fec­tions ex­e­cute’: What the coro­n­avirus pan­dem­ic means for the field of ...

6 years ago
Coronavirus
In Focus

Blast­ed by PhI­II fail­ure, a strug­gling Sage ax­es 340 staffers and bunkers down to sur­vive the storm

6 years ago
R&D

Well­come looks for back­ers of an $8B-plus Covid-19 fund; ReNeu­ron signs on an­oth­er phar­ma part­ner

6 years ago
News Briefing

Mer­ck-part­nered an­ti­body mak­er read­ies $300M IPO as HKEX picks up pace

6 years ago
Financing
China

Piv­otal fail­ure crum­bles stock for Michi­gan’s once-promis­ing Mil­len­do

6 years ago
R&D

Bio­phar­ma bil­lion­aires dom­i­nate Forbes' list of the world's top 10 wealth­i­est health­care ex­ecs — and the pan­dem­ic ...

6 years ago
People

Hos­pi­tals re­port ‘se­vere short­ages’ of Covid-19 tests, HHS sur­vey finds

6 years ago
Coronavirus

Covid-19 roundup: Ex-FDA com­mish Got­tlieb joins Re­pub­li­can gov­er­nor's coro­n­avirus team; Phar­ma ap­proval rat­ings ...

6 years ago
Coronavirus

Gilead gets in on the mi­cro­bio­me game with a $38M pact, up to $1.5B in mile­stones

6 years ago
Deals

An­oth­er pro­tein degra­da­tion biotech emerges, with the promise of a new ap­proach from an old hand

6 years ago
Financing
Startups
First page Previous page 852853854855856857858 Next page Last page
A service from the Financial Times